SpringWorks Therapeutics krijgt positief advies van de CHMP voor Mirdametinib voor de behandeling van volwassen en pediatrische patiënten met NF1-PN
- Als mirdametinib wordt goedgekeurd, zal het naar verwachting de eerste en enige therapie in de Europese Unie zijn met een handelsvergunning voor zowel volwassenen als kinderen met NF1-PN -…
SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
– Se approvato, mirdametinib sarà la prima e unica terapia nell'Unione europea a ottenere l'autorizzazione all'immissione in commercio sia per gli adulti che per i bambini affetti da NF1-PN –…
SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN
– im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN – – die Entscheidung der Europäischen Kommission wird…
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”),…
SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos
– Si se aprueba, se espera que el mirdametinib sea la primera y única terapia autorizada para el tratamiento de la NF1-NP en la Unión Europea, tanto para adultos como…
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”),…
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies…
PennantPark Floating Rate Capital Ltd.’s Unconsolidated Joint Venture, PennantPark Senior Secured Loan Fund I LLC Completes the Reset of its $315.8 Million Securitization, Lowering the Cost of Financing
MIAMI BEACH, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) today announced that PennantPark Senior Secured Loan Fund I LLC (“PSSL”) through…
Kelly Announces Participation in June 2025 Investor Conferences
TROY, Mich., May 22, 2025 (GLOBE NEWSWIRE) -- Kelly (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, today announced the Company will participate in two investor conferences in…
Form 8.5 (EPT/RI) – H & T Group
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY…